Literature DB >> 25022962

In situ cytokines (IL-4, IL-10, IL-12, IFN-γ) and chemokines (MCP-1, MIP-1α) gene expression in human Leishmania (Leishmania) Mexicana infection.

Guillermo Valencia-Pacheco1, Elsy Nalleli Loría-Cervera2, Erika Ivett Sosa-Bibiano3, Elsy B Canché-Pool4, Alberto Vargas-Gonzalez5, Peter C Melby6, Fernando J Andrade-Narvaez7.   

Abstract

Crucial to the defense against Leishmania is the ability of the host to mount a cell-mediated immune response capable of controlling and/or eliminating the parasite. The composition of the cell populations recruited in the early phase of the infection seems to be essential for defining the infection outcomes. The signals that initiate and regulate the early immune response and local accumulation of cell subsets in the skin are poorly understood. We previously studied the in situ expression of cytokine genes in patients with localized cutaneous leishmaniasis (LCL) caused by Leishmania (Leishmania) mexicana. In the present study we examined in situ cytokine (IL-4, IL-10, IL-12, IFN-γ) and chemokine (MCP-1, MIP-1α) gene expression in L. (L.) mexicana active LCL lesions, and in the delayed type hypersensitivity (DTH) skin response to Leishmania antigen in subjects with healed lesion and subclinical infection. Data regarding cytokines were similar to previous studies in patients with active LCL. There were no significant differences in the profile of cytokine and chemokine gene expression in DTH from subjects with healed or subclinical infection. IL-12 gene expression detected in both groups was similar. High expression of MCP-1 was detected in all patients with active LCL. There was no difference in the level of MCP-1 expression between the healed lesion and the subclinical infection groups (p = 0.876). IL-12 and MCP-1 in the absence of IFN-γ might be playing a crucial role in infection outcomes at skin level.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemokines; Cytokines; In situ; Leishmania mexicana; Localized cutaneous leishmaniasis

Mesh:

Substances:

Year:  2014        PMID: 25022962     DOI: 10.1016/j.cyto.2014.05.016

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  8 in total

1.  In situ immunopathological changes in cutaneous leishmaniasis due to Leishmania donovani.

Authors:  N H Manamperi; S Oghumu; N Pathirana; M V C de Silva; W Abeyewickreme; A R Satoskar; N D Karunaweera
Journal:  Parasite Immunol       Date:  2017-03       Impact factor: 2.280

Review 2.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

Review 3.  Brazilian Amazon Traditional Medicine and the Treatment of Difficult to Heal Leishmaniasis Wounds with Copaifera.

Authors:  Kelly Cristina Oliveira de Albuquerque; Andreza do Socorro Silva da Veiga; João Victor da Silva E Silva; Heliton Patrick Cordovil Brigido; Erica Patrícia Dos Reis Ferreira; Erica Vanessa Souza Costa; Andrey Moacir do Rosário Marinho; Sandro Percário; Maria Fâni Dolabela
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-17       Impact factor: 2.629

4.  Monocyte Chemotactic Protein 1 in Plasma from Soluble Leishmania Antigen-Stimulated Whole Blood as a Potential Biomarker of the Cellular Immune Response to Leishmania infantum.

Authors:  Ana V Ibarra-Meneses; Carmen Sanchez; Jorge Alvar; Javier Moreno; Eugenia Carrillo
Journal:  Front Immunol       Date:  2017-09-29       Impact factor: 7.561

5.  A semi-synthetic neolignan derivative from dihydrodieugenol B selectively affects the bioenergetic system of Leishmania infantum and inhibits cell division.

Authors:  Maiara Amaral; Fernanda S de Sousa; Thais A Costa Silva; Andrés Jimenez G Junior; Noemi N Taniwaki; Deidre M Johns; João Henrique G Lago; Edward A Anderson; Andre G Tempone
Journal:  Sci Rep       Date:  2019-04-16       Impact factor: 4.379

6.  Humoral immunity in leishmaniasis - Prevention or promotion of parasite growth?

Authors:  Ricardo Goncalves; Stephen M Christensen; David M Mosser
Journal:  Cytokine X       Date:  2020-10-31

Review 7.  Asymptomatic infection with American cutaneous leishmaniasis: epidemiological and immunological studies.

Authors:  Fernando J Andrade-Narvaez; Elsy Nalleli Loría-Cervera; Erika I Sosa-Bibiano; Nicole R Van Wynsberghe
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-10       Impact factor: 2.743

8.  Monocyte-Derived Signals Activate Human Natural Killer Cells in Response to Leishmania Parasites.

Authors:  Helena Messlinger; Heidi Sebald; Lukas Heger; Diana Dudziak; Christian Bogdan; Ulrike Schleicher
Journal:  Front Immunol       Date:  2018-01-24       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.